Clinical Trials

Free Web Hosting : Free Hosting : Credit Report : Low APR Credit Card

On this site new treatments (clinical trials) are listed, where responses of cancers have been observed. The treatments are arranged according to the cancer type response was observed. Links to the original publications are provided, which show the institutions and authors. There are only a few cancers listed yet but the list will be regularly updated. Be advised to always consult your health professional.

Brain Cancer

Complementary immunotherapy with a galactoside-specific lectin from mistletoe, ML-1 (German trial: response observed and prolongation of relapse-free survival.) Ior egf/r3, is a neutralizing murine monoclonal antibody (MAb) against EGF-R (Trial in Cuba, no obvious antitumor response but most patients had stable disease on 6 months evaluation and 2 survived several years.) IL-13 cytotoxin (Phase 1 trial initiated in 2001.) T cell adoptive immunotherapy of newly diagnosed gliomas (For newly diagnosed patients, several objective responses were observed.)
Kidney Cancer

interleukin-2, interferon-alpha2a and 5-fluorouracil combination clinical trial (metastatic, several complete and partial responses, stable disease. German trial) Interferon, 13-cis-retinoic acid (13-CRA) therapy (30% response rate reported.)
Leukemia

Irofulven (MGI 114), an acylfulvene illudin analog (One patient with primary resistant AML achieved complete remission.)
Lung Cancer

Sequential topotecan, carboplatin and etoposide (Non small cell and small cell lung cancer: complete and partial responses.)
Ovarian Cancer

NSC 655649, a rebeccamycin analog (Antitumor activity observed in some patients.)
Pancreas Cancer

9-nitrocamptothecin (Increase in survival, about 60% responded to treatment) topotecan, gemcitabine combination (Partial response and disease stabilization.)